Global Comprehensive Metabolic Panel (CMP) Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Disease;
Kidney Disease, Liver Disease, Diabetes, and Others.By Analytes;
K+, Na+, Cl-, CO2, and Glucose.By Test Type;
Proteins, Electrolytes, Kidney Tests, Liver Functional Tests, and Glucose.By End User;
Laboratories and PoC.By Geography;
North America, Europe, Asia Pacific, Middle East, Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Comprehensive Metabolic Panel (CMP) Testing Market (USD Million), 2021 - 2031
In the year 2023, the Global Comprehensive Metabolic Panel (CMP) Testing Market was valued at USD 14,899.28 million. The size of this market is expected to increase to USD 24,718.63 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 7.5%.
The global Comprehensive Metabolic Panel (CMP) testing market is a crucial segment of the healthcare diagnostics industry, providing essential information for the diagnosis and management of various diseases. CMP tests evaluate several components in the blood, including glucose, calcium, proteins, and electrolytes, along with kidney and liver function markers. These tests are pivotal for routine health assessments, aiding in the early detection of conditions like diabetes, liver disease, and kidney dysfunction. The growing prevalence of chronic diseases and the increasing emphasis on preventive healthcare have significantly fueled the demand for CMP testing worldwide.
Technological advancements in diagnostic equipment and testing methodologies have further propelled the market. Innovations such as automated analyzers and point-of-care testing devices have enhanced the accuracy, efficiency, and accessibility of CMP tests. These advancements not only streamline the testing process but also reduce turnaround times, making it easier for healthcare providers to deliver timely and effective patient care. The integration of artificial intelligence and machine learning in diagnostic procedures is anticipated to drive the market forward by providing more precise and comprehensive analysis.
Geographically, the CMP testing market exhibits a diverse landscape with significant growth opportunities across various regions. North America leads the market due to its well-established healthcare infrastructure, high awareness levels, and substantial investment in healthcare technologies. Europe follows closely, driven by similar factors. Meanwhile, emerging economies in Asia-Pacific and Latin America are witnessing rapid market growth, spurred by improving healthcare facilities, increasing healthcare expenditure, and rising awareness about early disease detection and management. As global healthcare systems continue to evolve, the demand for comprehensive metabolic panel testing is expected to expand, reinforcing its integral role in modern diagnostics.
Global Comprehensive Metabolic Panel (CMP) Testing Market Recent Developments
-
In February 2022, Abbott teamed up with leading health tech companies—BeatO, PharmEasy, GOQii, Sugar.fit, 1MG, Zyla Health, Fitterfly, and HealthifyMe—to revolutionize comprehensive diabetes management and treatment
-
In December 2021, Quest Diagnostics acquired Labtech Diagnostics' assets, expanding its reach in South and North Carolina, Georgia, and Florida. This acquisition enhances access to diagnostic innovations, improving healthcare across the Southeast.
Segment Analysis
The Disease segmentation focuses on the various medical conditions for which CMP testing is utilized. CMP testing is critical for diagnosing and monitoring diseases such as diabetes, kidney disorders, liver diseases, cardiovascular conditions, and metabolic disorders. The test provides essential data about the body's chemical balance and organ function, making it indispensable for healthcare professionals in assessing the progression of these diseases. By segmenting the market by disease, it becomes clear that the demand for CMP testing is particularly high in patients with chronic conditions such as diabetes and kidney-related diseases, where regular monitoring of metabolic parameters is vital.
In the Analytes segmentation, the focus is on the specific substances measured during CMP testing. Analytes typically include glucose, calcium, albumin, total protein, sodium, potassium, carbon dioxide, chloride, blood urea nitrogen (BUN), creatinine, and liver enzymes. These analytes provide a comprehensive view of the body's metabolic state, helping physicians diagnose a range of conditions and assess kidney, liver, and electrolyte functions. Understanding the types of analytes measured is crucial for determining the clinical relevance of CMP tests, especially in monitoring patients with multiple health concerns or those undergoing treatment for chronic conditions.
The Test Type segmentation divides the CMP testing market based on the variations in the testing methods and technologies employed. Traditional CMP tests are primarily laboratory-based, requiring blood samples for analysis, while emerging trends include point-of-care (POC) testing options that provide faster results in clinical settings. These advanced testing methods are particularly useful for emergency care or situations where rapid diagnosis is necessary. The test type segmentation highlights the ongoing innovation in diagnostic tools, as the market sees increasing adoption of automated and portable testing solutions to improve diagnostic accuracy and convenience.
In the End User segmentation, the market is categorized by the different healthcare providers that utilize CMP tests. Key end users include hospitals, diagnostic laboratories, clinics, and research institutions. Hospitals are major consumers of CMP tests, as they are used regularly in inpatient and outpatient settings to monitor and diagnose a variety of conditions. Diagnostic laboratories also play a critical role in processing CMP tests for a wide range of patients. Clinics and research institutions further contribute to the market, particularly in specialized areas of metabolic research and outpatient care. This segmentation emphasizes the broad applicability of CMP testing across different healthcare environments.
Finally, the Geography segmentation explores the global reach of the CMP testing market, with key regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe are leading regions due to advanced healthcare systems, high diagnostic testing standards, and widespread adoption of CMP tests in clinical practices. In Asia Pacific, the growing healthcare infrastructure, increasing prevalence of chronic diseases, and rising healthcare awareness are expected to drive market growth. Latin America and the Middle East and Africa present emerging markets where improved healthcare access and the need for diagnostic testing are contributing to increased demand for CMP testing services.
Global Comprehensive Metabolic Panel (CMP) Testing Segment Analysis
The Global Comprehensive Metabolic Panel (CMP) Testing Market Has Been Segmented By Disease, Analytes, Test Type, End User and Geography.
Global Comprehensive Metabolic Panel (CMP) Testing Market, Segmentation by Disease
The Global Comprehensive Metabolic Panel (CMP) Testing Market Has Been Segmented By Disease into Kidney Disease, Liver Disease, Diabetes and Others.
The global Comprehensive Metabolic Panel (CMP) testing market is witnessing significant growth, driven by the increasing prevalence of chronic diseases such as kidney disease, liver disease, diabetes, and other metabolic disorders. CMP tests are crucial for diagnosing and monitoring these conditions as they provide a broad overview of a patient’s metabolic state, including electrolyte balance, kidney and liver function, blood sugar levels, and protein levels. The rising incidence of kidney diseases, attributed to factors like hypertension, diabetes, and aging populations, has notably escalated the demand for CMP testing. The early detection and ongoing monitoring facilitated by CMP tests are essential in managing kidney diseases, thereby driving market growth in this segment.
Liver disease is another major segment propelling the growth of the CMP testing market. Liver function tests are a critical component of the CMP, helping in the diagnosis and management of various liver conditions such as hepatitis, cirrhosis, and fatty liver disease. The increase in alcohol consumption, the prevalence of hepatitis infections, and the rising incidence of obesity-related liver conditions are contributing to the surge in demand for CMP testing. Early diagnosis through CMP can lead to timely interventions, reducing the risk of severe liver damage and improving patient outcomes, thus fueling market expansion.
Diabetes management represents a significant portion of the CMP testing market. CMP tests are essential for diabetes patients as they help monitor glucose levels and kidney function, which can be affected by the disease. The global rise in diabetes cases, driven by lifestyle changes, increasing obesity rates, and genetic factors, has amplified the need for regular metabolic monitoring. CMP tests assist in the early detection of complications related to diabetes, enabling healthcare providers to adjust treatment plans promptly. The growing awareness about the importance of regular health check-ups and the increasing adoption of preventive healthcare practices are further contributing to the growth of the CMP testing market.
Global Comprehensive Metabolic Panel (CMP) Testing Market, Segmentation by Analytes
The Global Comprehensive Metabolic Panel (CMP) Testing Market Has Been Segmented By Analytes into K+, Na+, Cl-, CO2 and Glucose.
The Global Comprehensive Metabolic Panel (CMP) Testing Market, segmented by analytes, encompasses a wide range of diagnostic evaluations crucial for assessing overall health and detecting various medical conditions. Among these analytes, potassium (K+), sodium (Na+), chloride (Cl-), carbon dioxide (CO2), and glucose are pivotal. Potassium testing is essential for monitoring cardiac and muscle function, as abnormal levels can indicate conditions such as hyperkalemia or hypokalemia, which can lead to severe cardiac issues. Sodium tests are fundamental for evaluating electrolyte balance and kidney function, with deviations potentially pointing to disorders like hyponatremia or hypernatremia. Similarly, chloride tests help assess acid-base balance and hydration status, with abnormal levels often linked to kidney disease, respiratory issues, or metabolic acidosis/alkalosis.
The carbon dioxide test, which measures bicarbonate levels in the blood, is critical for evaluating the body's acid-base balance. This parameter is particularly significant in diagnosing and managing conditions like metabolic alkalosis, respiratory acidosis, and chronic obstructive pulmonary disease (COPD). Glucose testing, perhaps one of the most widely known CMP components, is indispensable for diagnosing and monitoring diabetes mellitus. Abnormal glucose levels can indicate hyperglycemia or hypoglycemia, each requiring prompt medical intervention to prevent severe complications such as diabetic ketoacidosis or hypoglycemic coma.
The market for CMP testing is expanding due to the rising prevalence of chronic diseases, increasing awareness about preventive healthcare, and advancements in diagnostic technologies. The integration of automated analyzers and point-of-care testing devices has significantly improved the efficiency and accessibility of CMP tests, facilitating timely diagnosis and treatment. The growing geriatric population, who are more susceptible to metabolic and chronic conditions, further drives the demand for CMP testing. This comprehensive approach to health assessment underscores the importance of routine metabolic panel testing in clinical practice, enabling healthcare providers to deliver more accurate diagnoses and personalized treatment plans.
Global Comprehensive Metabolic Panel (CMP) Testing Market, Segmentation by Test Type
The Global Comprehensive Metabolic Panel (CMP) Testing Market Has Been Segmented By Test Type into Proteins, Electrolytes, Kidney Tests, Liver Functional Tests and Glucose.
The Global Comprehensive Metabolic Panel (CMP) Testing Market is segmented into various test types, each addressing distinct biochemical markers and bodily functions. The first category is proteins, which typically include albumin and total protein tests. These tests are critical for diagnosing a range of conditions, such as liver disease, kidney disorders, and malnutrition. Albumin, the most abundant protein in the blood, helps maintain osmotic pressure, while total protein tests measure the overall amount of protein in the blood, including albumin and globulin. Abnormal protein levels can indicate chronic illnesses, infections, and other health conditions, making protein testing a vital component of CMP.
Electrolytes constitute another essential segment of CMP testing, involving the measurement of sodium, potassium, chloride, and bicarbonate levels. These tests are crucial for maintaining fluid balance, nerve function, and muscle activity. Electrolyte imbalances can result from a variety of causes including dehydration, kidney disease, and metabolic disorders. Sodium and potassium levels, in particular, are closely monitored to manage conditions like hypertension and cardiac arrhythmias. By identifying imbalances early, electrolyte tests help in the prompt management of potentially life-threatening conditions.
Kidney and liver functional tests are pivotal in the CMP market due to their roles in assessing organ function. Kidney tests typically include blood urea nitrogen (BUN) and creatinine, which indicate how well the kidneys are filtering waste from the blood. Liver function tests measure enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which can reveal liver damage from conditions like hepatitis and cirrhosis. Glucose tests are integral in CMP, as they measure blood sugar levels, aiding in the diagnosis and management of diabetes. Together, these tests provide a comprehensive overview of a patient's metabolic health, facilitating early diagnosis and effective treatment planning across various medical conditions.
Global Comprehensive Metabolic Panel (CMP) Testing Market, Segmentation by End User
The Global Comprehensive Metabolic Panel (CMP) Testing Market Has Been Segmented By End User into Laboratories and PoC.
The Global Comprehensive Metabolic Panel (CMP) Testing Market, when segmented by end users into laboratories and point-of-care (PoC) settings, showcases distinct growth dynamics driven by technological advancements and changing healthcare needs. Laboratories, being the traditional backbone of diagnostic services, continue to dominate the CMP testing market. These facilities offer high accuracy and comprehensive analysis due to their access to advanced analytical instruments and skilled personnel. Laboratories cater to a wide range of tests, including CMP, and their ability to handle high volumes of samples ensures a steady demand. The extensive use of automated systems in laboratories not only enhances the precision of results but also streamlines workflow, reducing turnaround times and costs.
The point-of-care (PoC) segment is witnessing rapid growth, propelled by the rising demand for immediate diagnostic results and the convenience of decentralized testing. PoC testing allows healthcare providers to conduct CMP tests at or near the patient’s location, leading to quicker clinical decisions and improved patient management. This segment benefits from innovations in portable diagnostic devices and user-friendly interfaces that make it feasible for non-laboratory settings, such as clinics, emergency rooms, and even home healthcare.
The increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, fuels the demand for CMP testing across both laboratories and PoC settings. Each segment faces unique challenges. Laboratories must constantly update their technologies and manage high operational costs, while PoC testing needs to ensure regulatory compliance and accuracy standards comparable to traditional lab tests. The market's growth is also influenced by the rising awareness of preventive healthcare, expanding healthcare infrastructure in emerging markets, and the integration of advanced technologies like artificial intelligence and telemedicine, which enhance both laboratory and PoC testing capabilities. This comprehensive approach to CMP testing ensures that both segments will continue to play pivotal roles in the global healthcare landscape.
Global Comprehensive Metabolic Panel (CMP) Testing Market, Segmentation by Geography
The Global Comprehensive Metabolic Panel (CMP) Testing Market Has Been Segmented By Geography into five regions; North America, Europe, Asia Pacific, Middle East, Africa and Latin America.
Global Comprehensive Metabolic Panel (CMP) Testing Market Share (%), by Geographical Region, 2024
The Global Comprehensive Metabolic Panel (CMP) Testing Market can be segmented geographically into five key regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. North America holds a significant share of the market due to advanced healthcare infrastructure, high healthcare expenditure, and the presence of major market players. The United States, in particular, leads the region with a robust demand for CMP tests driven by a high prevalence of chronic diseases such as diabetes, cardiovascular conditions, and liver diseases. Increasing awareness among patients and healthcare professionals regarding the importance of routine metabolic screening further propels market growth in this region.
Europe represents another vital region for the CMP testing market, characterized by substantial healthcare investments and well-established diagnostic sectors. Countries like Germany, the UK, and France are at the forefront due to their advanced medical technologies and comprehensive healthcare systems. The aging population in Europe, coupled with rising incidences of chronic illnesses, is a key factor driving the demand for CMP testing. Initiatives by governments and private entities to promote early diagnosis and preventive healthcare contribute significantly to the market expansion in this region.
The Asia Pacific region is expected to witness the fastest growth in the CMP testing market, owing to increasing healthcare awareness, improving medical infrastructure, and a rising burden of chronic diseases. Countries such as China, India, and Japan are leading this growth due to their large populations and increasing healthcare expenditures. The growing middle class and rising health consciousness among individuals are leading to higher demand for routine health check-ups, including CMP tests. In the Middle East & Africa and Latin America, the market is also anticipated to grow steadily due to improving healthcare facilities, rising prevalence of metabolic disorders, and increased government efforts to enhance healthcare services. Despite certain economic and infrastructural challenges, these regions offer substantial growth opportunities for CMP testing as awareness and access to healthcare services improve.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Comprehensive Metabolic Panel (CMP) Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Increasing Geriatric Population
- Rising Prevalence of Chronic Diseases
- Advancements in Diagnostic Technologies
-
Growing Awareness and Health Check-up Programs: Growing awareness and health check-up programs play a pivotal role in the expansion of the global Comprehensive Metabolic Panel (CMP) testing market. As the public becomes more educated about the importance of preventive healthcare, there is an increasing demand for routine health screenings, including CMP tests. These tests provide critical insights into an individual's metabolic health, including liver function, kidney function, and electrolyte balance, which are essential for diagnosing and managing various health conditions. Public health campaigns and educational initiatives have significantly contributed to the growing awareness, emphasizing the benefits of early detection and management of metabolic disorders.
Healthcare providers and organizations worldwide are intensifying their efforts to promote regular health check-ups through community outreach programs, free or subsidized screening events, and collaborations with schools and workplaces. These initiatives are designed to make CMP testing more accessible to diverse populations, especially in underserved areas where healthcare access may be limited. By reducing financial and logistical barriers, these programs ensure that more people can benefit from comprehensive health assessments, leading to earlier intervention and better health outcomes. Partnerships with non-governmental organizations and public health institutions help amplify these efforts, reaching a broader audience and fostering a culture of proactive health management.
Technological advancements and digital health tools have further facilitated the growth of the CMP testing market. The integration of mobile health applications and telemedicine services allows individuals to easily schedule and track their health check-ups, including CMP tests. These platforms often provide educational resources and personalized reminders, enhancing patient engagement and compliance with recommended health screenings. As a result, the combination of increased awareness, strategic health check-up programs, and technological innovations is driving the global demand for CMP testing, ultimately contributing to improved public health and the early detection of metabolic disorders.
Restraints:
- Technological Integration in Healthcare
- Rising Adoption of Personalized Medicine
- Increasing Demand for Preventive Healthcare
-
Growing Number of Laboratories and Diagnostic Centers: The Global Comprehensive Metabolic Panel (CMP) Testing Market has witnessed a surge in the number of laboratories and diagnostic centers, reflecting the increasing demand for advanced diagnostic solutions worldwide. As healthcare systems evolve and populations age, the need for comprehensive metabolic panels becomes paramount in managing chronic conditions and preventing diseases. These panels provide a comprehensive analysis of a patient's metabolic status, aiding healthcare professionals in diagnosing and monitoring various disorders such as diabetes, kidney disease, and liver dysfunction.
The proliferation of laboratories and diagnostic centers offering CMP testing services can be attributed to several factors. Advancements in technology have made diagnostic procedures more accurate, efficient, and accessible, driving healthcare providers to invest in modern equipment and infrastructure. Rising awareness among both healthcare professionals and patients regarding the importance of early disease detection and preventive healthcare measures has fueled the demand for comprehensive metabolic panels. The globalization of healthcare services and increasing healthcare expenditure in emerging markets have created lucrative opportunities for diagnostic service providers to expand their operations and cater to a broader patient base.
Collaborations between diagnostic companies and healthcare institutions, as well as strategic partnerships with pharmaceutical companies, have further accelerated the growth of CMP testing facilities globally. These collaborations often facilitate research and development efforts aimed at enhancing the diagnostic accuracy and scope of metabolic panels, driving innovation in the field. Regulatory initiatives aimed at standardizing diagnostic procedures and ensuring quality assurance have encouraged the establishment of accredited laboratories and diagnostic centers offering CMP testing services. Overall, the growing number of laboratories and diagnostic centers for CMP testing signifies a positive trend towards enhancing healthcare accessibility, improving patient outcomes, and advancing the field of clinical diagnostics on a global scale.
Opportunities:
- Consent and Confidentiality
- Disruption in Supply Chains
- Shift in Healthcare Priorities
-
Long-Term Implications on CMP Testing Market: The Global Comprehensive Metabolic Panel (CMP) Testing Market is poised for significant long-term implications, driven by various factors that are reshaping the healthcare landscape. As technology advances and healthcare systems evolve, the demand for comprehensive metabolic panel testing is likely to rise steadily. One crucial aspect driving this growth is the increasing prevalence of chronic diseases such as diabetes, kidney disorders, and liver diseases worldwide. CMP testing plays a pivotal role in diagnosing and monitoring these conditions, thus becoming an integral part of routine healthcare protocols. This sustained demand is expected to fuel market expansion over the long term.
The shift towards preventive healthcare strategies is anticipated to further propel the CMP testing market forward. With a growing emphasis on early detection and proactive management of health conditions, comprehensive metabolic panel testing emerges as a valuable tool for healthcare providers. By enabling timely identification of metabolic imbalances and abnormalities, CMP testing aids in preemptive interventions, potentially reducing healthcare costs and improving patient outcomes in the long run. This trend towards preventive care is likely to sustain the demand for CMP testing services, driving market growth over the foreseeable future.
The advent of personalized medicine and the integration of advanced technologies such as artificial intelligence (AI) and machine learning are poised to revolutionize the CMP testing landscape. These innovations offer unprecedented opportunities to enhance the accuracy, efficiency, and customization of metabolic panel testing, thereby catering to individual patient needs more effectively. With the potential to streamline workflows, optimize resource utilization, and deliver actionable insights, AI-driven CMP testing solutions are expected to gain traction, shaping the market dynamics in the long term. Advancements in data analytics and connectivity are likely to facilitate seamless integration of CMP testing into broader healthcare ecosystems, fostering collaboration among stakeholders and driving innovation in diagnostics and patient care.
Competitive Landscape Analysis
Key players in Global Comprehensive Metabolic Panel (CMP) Testing Market include:
- DeRoyal
- Albert David Ltd
- Braun Melsungen AG
- Terumo Corporation
- Connecticut Hypodermics Inc.
- Insulet
- Septodont
- Medtronic
- BD
- Schott AG
- Cardinal Health
- Smiths Medical
- Others
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysi
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Disease
- Market Snapshot, By Test Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Comprehensive Metabolic Panel (CMP) Testing Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increasing Geriatric Population
-
Rising Prevalence of Chronic Diseases
-
Advancements in Diagnostic Technologies
-
Growing Awareness and Health Check-up Programs
-
- Restraints
-
Technological Integration in Healthcare
-
Rising Adoption of Personalized Medicine
-
Increasing Demand for Preventive Healthcare
-
Growing Number of Laboratories and Diagnostic Centers
-
- Opportunities
-
Consent and Confidentiality
-
Disruption in Supply Chains
-
Shift in Healthcare Priorities
-
Long-Term Implications on CMP Testing Market
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Comprehensive Metabolic Panel (CMP) Testing Market, By Disease, 2021 - 2031 (USD Million)
- Kidney Disease
- Liver Disease
- Diabetes
- Others
- Global Comprehensive Metabolic Panel (CMP) Testing Market, By Analytes, 2021 - 2031 (USD Million)
- K+
- Na+
- Cl-
- CO2
- Glucose
- Global Comprehensive Metabolic Panel (CMP) Testing Market, By Test Type, 2021 - 2031 (USD Million)
- Proteins
- Electrolytes
- Kidney Tests
- Liver Functional Tests
- Glucose
- Global Comprehensive Metabolic Panel (CMP) Testing Market, By End User, 2021 - 2031 (USD Million)
- Laboratories
- PoC
- Global Comprehensive Metabolic Panel (CMP) Testing Market, By Geography, 2021 - 2031 (USD Million)
-
North America
-
United States
-
Canada
-
-
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Nordic
-
Benelux
-
Rest of Europe
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia/New Zealand
-
South Korea
-
ASEAN
-
Rest of Asia Pacific
-
-
Middle East & Africa
-
GCC
-
Israel
-
South Africa
-
Rest of Middle East & Africa
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
Rest of Latin America
-
-
- Global Comprehensive Metabolic Panel (CMP) Testing Market, By Disease, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- DeRoyal
- Albert David Ltd
- Braun Melsungen AG
- Terumo Corporation
- Connecticut Hypodermics Inc.
- Insulet
- Septodont
- Medtronic
- BD
- Schott AG
- Cardinal Health
- Smiths Medical
- Others
- Company Profiles
- Analyst Views
- Future Outlook of the Market